Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

The S&P/ASX 300 Index (ASX: XKO) is down 0.3% today despite the best efforts of this rocketing ASX 300 healthcare share.

The surging stock in question is clinical-stage biotech company Immutep Ltd (ASX: IMM).

Immutep shares closed yesterday trading for 25.5 cents. In early morning trade on Tuesday, shares are changing hands for 32.5 cents apiece, up 27.5%.

This outperformance follows news of a new strategic collaboration.

Here’s what’s happening.

ASX 300 healthcare share surges on global expansion potential

Investors are piling into Immutep shares today after the ASX 300 healthcare share reported that it has entered into a strategic collaboration and exclusive licensing agreement with an Indian-based global pharmaceutical company, Dr. Reddy’s.

The agreement is for the development and commercialisation of Immutep’s Eftilagimod Alfa (efti) cancer treatment in all countries outside North America, Europe, Japan, and Greater China.

The ASX 300 healthcare share will retain its rights on efti in those markets. Immutep also retains all its global manufacturing rights for efti across all markets. The company will supply the product to Dr. Reddy’s in the licensed markets.

Immutep describes efti as a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda) and chemotherapy as first-line therapy for non-small cell lung cancer.

The company highlighted that efti is also being investigated in other indications, including head and neck cancer, breast cancer, and soft tissue sarcoma.

Under the agreement with Dr. Reddy’s, Immutep will receive an upfront payment of US$20 million (AU$30.2 million). The company said it may also receive potential regulatory development and commercial milestone payments of up to US$349.5 million, as well as double-digit royalties on commercial sales in these markets.

What did management say?

Commenting on the collaboration sending the ASX 300 healthcare share rocketing today, Immutep CEO Marc Voigt said, “This agreement with Dr. Reddy’s marks a significant milestone for Immutep and further validates the potential of efti.”

Voigt continued:

Dr. Reddy’s proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe.

Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and Japan, and ensures we remain very well-positioned for future value creation.

M.V. Ramana, CEO Branded Markets Dr. Reddy’s, noted, “”This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment.”

Ramana added:

Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialisation of this promising cancer therapy in the licensed markets.

The post Guess which ASX 300 healthcare share is rocketing 28% on global expansion news appeared first on The Motley Fool Australia.

More reading

• This soaring ASX mining stock backed by billionaire Gina Rinehart just unveiled “exceptional” news
• Up 24% in a year! The red-hot Telstra share price is smashing BHP, Westpac and Coles
• The sleeper defence stock set to explode? Up 240% in 2025, and poised to fire again!
• Liontown clinches Canmax deal: key details for investors
• Why are Liontown shares rising today and up 18% this week?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.